Bariatric Surgery for Type 2 Diabetes: Results and Cost

Bariatric surgery for type 2 diabetes works by changing the hormones the gut releases after a meal, not only by reducing weight. Dr. Rakesh Durkhure, Head - General, MI & Bariatric Surgery (Unit IV), Artemis Hospitals, Gurugram, India, presented data showing that a gastric bypass increases insulin sensitivity 2.7 times, against 1.2 times after a sleeve gastrectomy, and puts the cost of a bypass at about $5,500 to $6,000.

This article explains the hormonal mechanism, the remission and outcome figures he presented, and his comparison of a one-time operation with lifelong weight loss medication. It is part of a three-part series: the complete guide to obesity and metabolic syndrome covers diagnosis and referral, and balloon vs sleeve vs gastric bypass covers the procedures, selection criteria and safety.

How the gut controls appetite and blood sugar

The gut controls appetite and blood sugar through hormones: the intestine is an endocrine organ, a gland as well as a digestive tube. It releases many hormones in response to food and to obesity, and two groups matter most for weight and diabetes.

Ghrelin, the hunger hormone. Dr. Durkhure singled out ghrelin, secreted by the stomach, which acts on the brain and tells it to eat more. Most of the body's ghrelin is produced in the upper part of the stomach (the fundus), the part removed in a sleeve gastrectomy, which is one reason patients feel less hungry after the operation.

The incretins and satiety hormones. After a gastric bypass, food reaches the lower small intestine faster and triggers a larger release of what Dr. Durkhure called the "good hormones", chiefly glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). GLP-1 signals the pancreas to make more insulin and helps blood sugar fall, and GLP-1 and PYY both increase the feeling of fullness.

This is the central insight of metabolic surgery: rerouting food changes the hormonal signals that set appetite and glucose control, which is why the effect on diabetes often appears before significant weight has been lost.

Insulin sensitivity after gastric bypass vs sleeve gastrectomy

Gastric bypass improves insulin sensitivity far more than a sleeve gastrectomy or diabetes medicines, on the data Dr. Durkhure presented. Insulin resistance is the failure of the body's tissues to respond normally to insulin, and it sits at the heart of type 2 diabetes. The data Dr. Durkhure presented compare the treatments:

• Gastric bypass: insulin sensitivity increases 2.7 times.
• Sleeve gastrectomy: insulin sensitivity increases only 1.2 times.
• Diabetes medicines: they lower the patient's blood sugar, and some improve insulin sensitivity, but only while they are taken; they rarely produce lasting remission.

The distinction is between controlling a number and changing the disease. A tablet that lowers glucose works only while it is taken; an operation that improves insulin sensitivity alters the physiology that produced the high glucose in the first place.

Bariatric surgery for type 2 diabetes: remission after gastric bypass

After gastric bypass, type 2 diabetes went away completely in 42% of patients on the comparison Dr. Durkhure presented. Diabetes remission, often called diabetes reversal, means normal or near-normal blood sugar without diabetes medication. That comparison set surgery against medical therapy, and the 42% remission came with a very large reduction in HbA1c (glycated haemoglobin, the measure of average blood sugar over about three months). On the same comparison, intensive medical treatment reached that level of control in far fewer patients, and the gap widened over longer follow-up. Glucose-lowering medicines remain the standard treatment for type 2 diabetes and reduce its complications while they are taken, but they rarely produce remission.

His own practice reflects this. He reported that after surgery, patients who were taking insulin come off it, and in patients on tablets the diabetes can go away completely. He has performed about 560 weight loss operations in total, including patients operated on specifically for diabetes.

Results vary between patients. Remission is generally more likely when diabetes is of shorter duration and the pancreas still produces a reasonable amount of its own insulin, and less likely in long-standing diabetes already requiring insulin. Remission also requires continued follow-up, because blood sugar can rise again over the years.

Bariatric surgery outcomes: sleep apnoea, blood pressure and lipids

Beyond diabetes, the figures Dr. Durkhure presented show bariatric surgery improving sleep apnoea, blood pressure, blood fats and quality of life. He presented two sets of outcome figures. The first showed the general improvement in obesity-related conditions after bariatric surgery:

• Obstructive sleep apnoea: resolved in about 86% of patients.
• Quality of life: improved in 94 to 95% of patients.
• Diabetes: improved in 83% of patients.
• Migraine and headache: reduced.
• Depression: improved.
• Mortality: reduced after surgery.

The second compared Roux-en-Y gastric bypass with laparoscopic sleeve gastrectomy, and showed higher success rates with the bypass. For gastric bypass, the figures he read out were:

• Blood fats (lipids): reduction in 92 to 93% of patients.
• Diabetes: reduction in 94% of patients.
• Blood pressure: 84% of patients stop taking antihypertensive medication.
• Excess weight loss (the share of surplus weight above a healthy weight that is lost): the greatest of the procedures compared.

The two diabetes figures, 83% and 94%, come from different datasets: the first covers bariatric surgery broadly, the second gastric bypass specifically. Both point the same way. For a patient whose obesity has produced diabetes, hypertension, abnormal lipids and sleep apnoea together, one operation addresses all four.

GLP-1 medicines: how they work and where they fall short

GLP-1 medicines work only while they are taken. The newer weight loss medicines, which Dr. Durkhure named as Mounjaro and Ozempic, mimic the "good hormones" that a bypass releases. They reduce appetite and food intake, slow the emptying of the stomach and increase insulin secretion. Ozempic (semaglutide) is a GLP-1 receptor agonist and Mounjaro (tirzepatide) acts on both the GLP-1 and GIP receptors; both are given as once-weekly injections. He described them as good medicines.

The limitation is permanence. In Dr. Durkhure's comparison, a patient on medication must keep taking it, and once it is stopped the weight starts to come back. Surgery, by contrast, is permanent, and in his experience patients are happier at the end of it. GLP-1 medicines and surgery are also compared in his later masterclass: see sleeve gastrectomy vs mini gastric bypass.

The cost of bariatric surgery in India

A gastric bypass, the option with the lowest relapse rate, costs about $5,500 to $6,000 from hospital admission to discharge, by the figures Dr. Durkhure gave in the live session. Travel to and from India is separate.

• Variation: the figure moves by about $500, at most $1,000, depending on the patient's body weight and on how much management their diabetes and breathing problems need.
• Other procedures: the other options cost somewhat less, roughly $1,000 less than a bypass.

The bariatric surgery cost page gives the wider picture for patients planning treatment.

Bariatric surgery vs lifelong medication: the cost over time

On Dr. Durkhure's figures, bariatric surgery pays for itself within about a year against lifelong weight loss medication. The comparison that matters to most families is the cost of a single operation against the cost of medication that never ends. Dr. Durkhure put the price of Ozempic or Mounjaro at about $500 a month in India, and noted that prices elsewhere may differ. Because the medication has to be continued indefinitely, he calculated that the cost of surgery is recovered within about one year of the medication it replaces.

After that, in his words, the patient needs only some vitamins and good, nutritious food, and no longer depends on the medicine. Over a working lifetime the gap is large: one hospital bill set against twelve monthly prescriptions every year, with the added benefit that surgery also treats sleep apnoea, blood pressure and blood fats.

Which patients with diabetes benefit most from surgery

The patients who benefit most are those with obesity and type 2 diabetes, often with hypertension or sleep apnoea. Drawing the threads together, Dr. Durkhure's analysis points to gastric bypass for this profile, because it offers the strongest hormonal effect and the lowest relapse, and he prefers it above about 125 kg. The selection criteria and the safety record are set out in balloon vs sleeve vs gastric bypass. The questions doctors raised in the session, including relapse and cost, are answered in the Live Discussion, and Dr. Durkhure's profile is on the doctor page.